Genes

19 drugs in development·14 companies·1 clinical trial

Drug Pipeline by Phase

Approved(5)

Drug	Company
ceftriaxone	Teva Pharmaceutical Industries Limited (TEVA)
cholbam	Mirum Pharmaceuticals, Inc. (MIRM)
Roxithromycin Dispersible Tablets	CHINA PHARMA HOLDINGS, INC. (CPHI)
sivextro	Curative Biotechnology Inc (CUBT)
Xepi®	Biofrontera Inc. (BFRI)

Phase 3(7)

Drug	Company
bisphosphonate	AMGEN INC (AMGN)
Bisphosphonate	Ultragenyx Pharmaceutical Inc. (RARE)
elagolix	AbbVie Inc. (ABBV)
romosozumab	AMGEN INC (AMGN)
setrusumab	Mereo BioPharma Group plc (MREO)
Setrusumab	Ultragenyx Pharmaceutical Inc. (RARE)
UX143	Ultragenyx Pharmaceutical Inc. (RARE)

Phase 2(1)

Drug	Company
Express Genes	Twist Bioscience Corp (TWST)

Phase 1(2)

Drug	Company
ATRN-119	Aprea Therapeutics, Inc. (APRE)
sar439459	Sanofi (SNY)

Preclinical(1)

Drug	Company
nc605	NextCure, Inc. (NXTC)

Unknown(3)

BioSniper tracks 19 drugs in development for Genes across 14 companies.

There are 1 clinical trial targeting Genes tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.